Encelta
Basel
About Encelta
Encelta T-cell therapy target and eliminate both blood cancers and solid tumors combined with bispecific antibodies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.7M
- Last round: Grant (May 2025)
- Website: startup.chencelta
Industries & Categories
Biopharma, Biotechnology, Health Care
Canonical: https://fsome.com/organization/encelta-85879 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.